{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05900986",
            "orgStudyIdInfo": {
                "id": "LS301-IT-B101"
            },
            "organization": {
                "fullName": "Integro Theranostics",
                "class": "INDUSTRY"
            },
            "briefTitle": "LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer",
            "officialTitle": "An Open-label, Single-arm, Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of LS301-IT in Female Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for Ductal Carcinoma in Situ (DCIS) or Stage I-II Primary Invasive Breast Cancer",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "it-in-partial-mastectomy-and-sentinel-lymph-node-biopsy-slnb-for-dcis-or-stage-i-ii-primary-invasive-breast-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-07-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-10",
            "studyFirstSubmitQcDate": "2023-06-02",
            "studyFirstPostDateStruct": {
                "date": "2023-06-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-20",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Integro Theranostics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The aim of this Phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) injection in female patients undergoing partial mastectomy for DCIS (whether or not undergoing planned SLNB) or Stage I-II primary invasive breast cancer undergoing SLNB. Safety is the primary objective of this study, followed by efficacy that will be assessed from fluorescence imaging observations and data.",
            "detailedDescription": "This is a Phase 1b/Phase 2, open-label study to investigate the use of LS301-IT (investigational medicinal product \\[IMP\\]), a fluorescence imaging agent used for visualization of tumor margins and SLNs in female patients with DCIS or Stage I-II, primary invasive carcinoma of the breast, for which the patient's primary surgical treatment is partial mastectomy.\n\nEligible patients will be enrolled into either:\n\n* Phase 1b (Period 1): dose finding (escalation/de-escalation), and dose timing adjustment;\n* Phase 2a (Period 2): expanded sample size based on acceptable dosing regimen, that being the dose level(s) and time interval between LS301-IT injection and surgery, determined in Period 1; or\n* Period 2b (Period 3): allow surgeon to make additional surgical decisions based on fluorescence imaging findings during surgery (Period 3 will not be opened until results are available from Periods 1 and 2 and further FDA consultation is obtained)."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Cancer",
                "DCIS",
                "Invasive Duct Carcinoma of Breast"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "LS301-IT",
                    "type": "EXPERIMENTAL",
                    "description": "LS301-IT will be adminstered by IV injection",
                    "interventionNames": [
                        "Drug: LS301-IT 0.025 mg/kg",
                        "Drug: LS301-IT 0.05 mg/kg",
                        "Drug: LS301-IT 0.075 mg/kg",
                        "Drug: LS301-IT 0.1 mg/kg"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "LS301-IT 0.025 mg/kg",
                    "description": "The dose of LS301-IT planned to be administered to the first cohort of patients is 0.025 mg/kg. Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased (by 50% as necessary). The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.",
                    "armGroupLabels": [
                        "LS301-IT"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "LS301-IT 0.05 mg/kg",
                    "description": "Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.",
                    "armGroupLabels": [
                        "LS301-IT"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "LS301-IT 0.075 mg/kg",
                    "description": "Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.",
                    "armGroupLabels": [
                        "LS301-IT"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "LS301-IT 0.1 mg/kg",
                    "description": "Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.",
                    "armGroupLabels": [
                        "LS301-IT"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Adverse Events",
                    "description": "Number of participants with treatment-related adverse events",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "Pharmacodynamics",
                    "description": "Tumor to non-tumor ratio fluorescence response",
                    "timeFrame": "during surgery"
                },
                {
                    "measure": "Pharmacodynamics",
                    "description": "Surgeon's assessment using a semi-quantitative scoring system of fluorescence compared with intraoperative and postoperative pathology assessments.",
                    "timeFrame": "During surgery"
                },
                {
                    "measure": "Cmax",
                    "description": "maximum observed plasma concentration main metabolite in plasma.",
                    "timeFrame": "24 hours"
                },
                {
                    "measure": "AUCinf",
                    "description": "area under the plasma concentration time curve from time 0 extrapolated to infinite time",
                    "timeFrame": "24 hours"
                },
                {
                    "measure": "AUClast",
                    "description": "area under the plasma concentration-time curve from time 0 to the last quantifiable plasma concentration",
                    "timeFrame": "24 hours"
                },
                {
                    "measure": "Tmax",
                    "description": "time to reach maximal plasma concentration (Tmax)",
                    "timeFrame": "24 hours"
                },
                {
                    "measure": "t1/2",
                    "description": "elimination/apparent terminal elimination half life",
                    "timeFrame": "24 hours"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* DCIS (whether or not undergoing planned SLNB) or patients with Stage I-II, primary invasive carcinoma of the breast undergoing SLNB for which the patient's primary surgical treatment is single breast partial mastectomy.\n* ECOG performance status of 0 to 2\n\nExclusion Criteria:\n\n* Contraindications for surgery.\n* Simultaneous bilateral lumpectomies and bilateral partial mastectomies.\n* History of drug-related anaphylactic reactions, including those attributed to indocyanine green (ICG) or other agents used in the study\n* Prior chemotherapy, endocrine therapy, or biologic therapy for current clinically or biopsy proven breast cancer for Period 1.\n* Open surgery in the ipsilateral breast within a period of 1 year before administration of LS301-IT.\n* History of radiation therapy to the chest.\n* The lymphatic imaging agent ICG cannot be used prior to the partial mastectomy and SLNB procedures on the day of surgery.",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "genderBased": true,
            "genderDescription": "female with breast cancer",
            "minimumAge": "18 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Nicole Peterson",
                    "role": "CONTACT",
                    "phone": "314-325-1800",
                    "email": "npeterson@kingdomcapital.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Dan Thompson",
                    "affiliation": "Integro Theranostics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Integro Theranostics Research Site #2",
                    "status": "RECRUITING",
                    "city": "Scottsdale",
                    "state": "Arizona",
                    "zip": "85260",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Integro Study Line",
                            "role": "CONTACT",
                            "phone": "314-325-1800",
                            "email": "npeterson@kingdomcapital.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.50921,
                        "lon": -111.89903
                    }
                },
                {
                    "facility": "Integro Theranostics Research Site #9",
                    "status": "RECRUITING",
                    "city": "Weston",
                    "state": "Florida",
                    "zip": "33331",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Integro Study Line",
                            "role": "CONTACT",
                            "phone": "314-325-1800",
                            "email": "npeterson@kingdomcapital.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 26.10037,
                        "lon": -80.39977
                    }
                },
                {
                    "facility": "Integro Theranostics Research Site #6",
                    "status": "RECRUITING",
                    "city": "Bronx",
                    "state": "New York",
                    "zip": "10461",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Integro Study Line",
                            "role": "CONTACT",
                            "phone": "314-325-1800",
                            "email": "npeterson@kingdomcapital.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.84985,
                        "lon": -73.86641
                    }
                },
                {
                    "facility": "Integro Theranostics Clinical Research Site #8",
                    "status": "RECRUITING",
                    "city": "Winston-Salem",
                    "state": "North Carolina",
                    "zip": "27103",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Integro Study LIne",
                            "role": "CONTACT",
                            "phone": "314-325-1800",
                            "email": "npeterson@kingdomcapital.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.09986,
                        "lon": -80.24422
                    }
                },
                {
                    "facility": "Integro Theranostics Research Site #10",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Integro Study Line",
                            "role": "CONTACT",
                            "phone": "314-325-1800",
                            "email": "npeterson@kingdomcapital.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Integro Theranostics Research Site #5",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19107",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Integro Study LIne",
                            "role": "CONTACT",
                            "phone": "314-325-1800",
                            "email": "npeterson@kingdomcapital.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Integro Theranostics Research Site #3",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75290",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Integro Study Line",
                            "role": "CONTACT",
                            "phone": "314-325-1800",
                            "email": "npeterson@kingdomcapital.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Integro Theronostics Research Site #1",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Integro Study Line",
                            "role": "CONTACT",
                            "phone": "314-325-1800",
                            "email": "npeterson@kingdomcapital.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                },
                {
                    "id": "D000044584",
                    "term": "Carcinoma, Ductal"
                },
                {
                    "id": "D000018270",
                    "term": "Carcinoma, Ductal, Breast"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000018299",
                    "term": "Neoplasms, Ductal, Lobular, and Medullary"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5535",
                    "name": "Carcinoma in Situ",
                    "relevance": "LOW"
                },
                {
                    "id": "M25356",
                    "name": "Carcinoma, Ductal",
                    "asFound": "Duct Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5542",
                    "name": "Carcinoma, Intraductal, Noninfiltrating",
                    "relevance": "LOW"
                },
                {
                    "id": "M20415",
                    "name": "Carcinoma, Ductal, Breast",
                    "asFound": "Invasive Duct Carcinoma of Breast",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}